NCM
ACET icon

Nantahala Capital Management’s Adicet Bio ACET Stock Holding History

Nantahala Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-19,409
Closed -$2.44M – 134
2021
Q3 		$2.44M Hold
19,409
– – 0.08% 100
2021
Q2 		$3.19M Sell
19,409
-5,333
-22% -$1.09M 0.09% 102
2021
Q1 		$5.18M Buy
24,742
+3,241
+15% +$744K 0.15% 82
2020
Q4 		$4.83M Sell
21,501
-4,448
-17% -$911K 0.15% 91
2020
Q3 		$4.94M Hold
25,949
– – 0.15% 85
2020
Q2 		$6.25M Buy
+25,949
New +$5.1M 0.19% 78

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Nantahala Capital Management's ACET Position: Q4 2021 in Review

Nantahala Capital Management sold out of Adicet Bio (ACET) in Q4 2021, closing a stake of 19,409 shares — an estimated $2.44M sold.

Nantahala Capital Management first reported a position in ACET in Q2 2020 and held it in 6 quarters. The position peaked at $6.25M in Q2 2020. 81 funds tracked by Wall St. Rank hold ACET as of Q4 2021.

  • Nantahala Capital Management reported no remaining Adicet Bio position as of Q4 2021 after selling out during the quarter.
  • Nantahala Capital Management sold 19,409 Adicet Bio shares in Q4 2021, an estimated $2.44M.
  • Nantahala Capital Management first reported a position in Adicet Bio in Q2 2020 and held it in 6 quarters.
  • Nantahala Capital Management's Adicet Bio position peaked at $6.25M in Q2 2020.
  • 81 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2021.

Based on Nantahala Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.